A2780cis cells were significantly less sensitive to cisplatin treatment compared with parental A2780 cells (p = .0055, t [2.5] = −9.1, Welch's two‐sample t‐test); however, parental A2780 and A2780cis cells were equally sensitive to KH‐4‐43 treatment (p = .91, t [4] = .12, Welch's two‐sample t‐test) (Figure 3D), highlighting the potential of targeting CRL4 in platinum‐refractory ovarian cancer and supporting the potential utility in both the front line and refractory settings. This evidence concerns the gene IL17RB and ovarian carcinoma.